{"preliminary_commentary":{"by_channel":{"youtube":8,"podcast":7,"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06350097\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TROPION-Lung14","nct_id":"NCT06350097","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-lung14-nct06350097. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TROPION-Lung14","arms":[{"description":"Participants in this group will receive osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion q3w of Day 1 of every 21-day cycle.","label":"Arm 1: Osimertinib in combination with Datopotamab Deruxtecan","type":"EXPERIMENTAL"},{"description":"Participants in this group will receive osimertinib 80 mg QD as oral tablet.","label":"Arm 2: Osimertinib monotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2031-08-29","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":582,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":["Osimertinib: Tagrisso, AZD9291"],"type":"DRUG"},{"name":"Datopotamab Deruxtecan","otherNames":["Dato-DXd, DS-1062a"],"type":"DRUG"}],"last_update":"2026-08-26","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-03-21","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of Progression Free Survival (PFS) by BICR in all randomised participants.","timeFrame":"It is anticipated that it will be performed approximately 3 years after the first participant is randomised."}],"references":[{"citation":"Lu S, Pulla MP, Mascarenhas E, Tanizaki J, Kim HR, Liu Y, Feng S, Zhang B, Toms L, Yang JC, Goldberg SB. TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer. Ther Adv Med Oncol. 2026 May 20;18:17588359261430561. doi: 10.1177/17588359261430561. eCollection 2026.","pmid":"42182601","type":"DERIVED"}],"start_date":{"date":"2024-04-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06350097"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-lung14-nct06350097"}